-
Patients with a first VTE event occurring in association with a reversible or time-limited risk factor should be treated with anticoagulants for at least three months, whereas patients with a first PE should be treated for at least six to 12 months; in fact, a case can be made for indefinite anticoagulant therapy in PE patients who have a great concern about recurrent PE and/or who are minimally concerned about the bleeding risk of anticoagulant therapy and the need for frequent determinations of the INR.
-
Female physicians have more than twice the rate of suicide as other professional women and are proportionally at greater risk compared with their male physician counterparts.
-
Axonal neuropathy is common in patients with biopsy-proven small vessel systemic vasculitis (SVSV), and responds to immunosuppressive therapy.
-
Two recent studies suggest that rapid TIA evaluation and treatment can reduce stroke risk.
-
Proteomic and molecular genetic testing is a critical part of the diagnostic algorithm for limb girdle muscular dystrophy (LGMD).
-
Acute and chronic head and face pain occur after craniotomies for a variety of intracranial lesions. Persistent postoperative pain is more common in women and is associated with depression and anxiety.
-
Increased levels of retinol in CSF in patients with IIH suggests that vitamin A may be involved in the pathogenesis of IIH.
-
Functional MRI (fMRI) measurements in unmedicated children with Tourette syndrome during cognitively difficult tasks suggest increased "direct" pathway activity in the basal ganglia, and possible compensatory mechanisms involving the subthalamic nucleus and prefrontal cortex.
-
It's time to redouble efforts to stem adolescent pregnancy. Preliminary birth statistics released by the Centers for Disease Control and Prevention indicate the U.S. birth rate rose by 3% between 2005 and 2006 among females 15-19 after dropping 34% between 1991 and 2005.
-
Over-the-counter contraceptive products that contain the spermicide nonoxynol-9 (N-9) now will carry a warning label to alert consumers that such products do not protect against sexually transmitted diseases (STDs) and HIV/AIDS, following a final ruling by the Food and Drug Administration (FDA).
